Prelude Therapeutics (PRLD)
Market Price (2/2/2026): $1.86 | Market Cap: $141.6 MilSector: Health Care | Industry: Biotechnology
Prelude Therapeutics (PRLD)
Market Price (2/2/2026): $1.86Market Cap: $141.6 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -26% | Weak multi-year price returns2Y Excs Rtn is -90%, 3Y Excs Rtn is -148% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -121 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1153% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 250% | Stock price has recently run up significantly6M Rtn6 month market price return is 123% | |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 132% | |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -954%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -955% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -83% | ||
| High stock price volatilityVol 12M is 195% | ||
| Key risksPRLD key risks include [1] a precarious financial position with a high risk of bankruptcy, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -26% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 250% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -90%, 3Y Excs Rtn is -148% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -121 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1153% |
| Stock price has recently run up significantly6M Rtn6 month market price return is 123% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 132% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -954%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -955% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -83% |
| High stock price volatilityVol 12M is 195% |
| Key risksPRLD key risks include [1] a precarious financial position with a high risk of bankruptcy, Show more. |
Stock Movement Drivers
Fundamental Drivers
The 16.4% change in PRLD stock from 10/31/2025 to 2/1/2026 was primarily driven by a 50.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 10312025 | 2012026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.59 | 1.85 | 16.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 7 | 10 | 50.0% |
| P/S Multiple | 17.3 | 13.4 | -22.3% |
| Shares Outstanding (Mil) | 76 | 76 | -0.2% |
| Cumulative Contribution | 16.4% |
Market Drivers
10/31/2025 to 2/1/2026| Return | Correlation | |
|---|---|---|
| PRLD | 16.4% | |
| Market (SPY) | 1.5% | 7.7% |
| Sector (XLV) | 7.3% | 8.0% |
Fundamental Drivers
The 137.2% change in PRLD stock from 7/31/2025 to 2/1/2026 was primarily driven by a 58.4% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 2012026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.78 | 1.85 | 137.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 7 | 10 | 50.0% |
| P/S Multiple | 8.5 | 13.4 | 58.4% |
| Shares Outstanding (Mil) | 76 | 76 | -0.2% |
| Cumulative Contribution | 137.2% |
Market Drivers
7/31/2025 to 2/1/2026| Return | Correlation | |
|---|---|---|
| PRLD | 137.2% | |
| Market (SPY) | 9.8% | 9.1% |
| Sector (XLV) | 19.2% | 8.8% |
Fundamental Drivers
The 68.2% change in PRLD stock from 1/31/2025 to 2/1/2026 was primarily driven by a 250.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312025 | 2012026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.10 | 1.85 | 68.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3 | 10 | 250.0% |
| P/S Multiple | 27.8 | 13.4 | -51.8% |
| Shares Outstanding (Mil) | 76 | 76 | -0.4% |
| Cumulative Contribution | 68.2% |
Market Drivers
1/31/2025 to 2/1/2026| Return | Correlation | |
|---|---|---|
| PRLD | 68.2% | |
| Market (SPY) | 16.0% | 14.4% |
| Sector (XLV) | 6.8% | 12.6% |
Fundamental Drivers
The -71.0% change in PRLD stock from 1/31/2023 to 2/1/2026 was primarily driven by a null change in the company's P/S Multiple.| (LTM values as of) | 1312023 | 2012026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.38 | 1.85 | -71.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 10 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 13.4 | |
| Shares Outstanding (Mil) | 47 | 76 | -37.7% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2023 to 2/1/2026| Return | Correlation | |
|---|---|---|
| PRLD | -71.0% | |
| Market (SPY) | 76.6% | 18.0% |
| Sector (XLV) | 21.4% | 16.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| PRLD Return | -83% | -51% | -29% | -70% | 127% | -34% | -97% |
| Peers Return | 21% | -17% | 2% | -17% | 9% | 2% | -5% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 2% | 86% |
Monthly Win Rates [3] | |||||||
| PRLD Win Rate | 17% | 25% | 42% | 42% | 58% | 0% | |
| Peers Win Rate | 52% | 52% | 40% | 47% | 57% | 60% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 100% | |
Max Drawdowns [4] | |||||||
| PRLD Max Drawdown | -83% | -68% | -72% | -81% | -52% | -38% | |
| Peers Max Drawdown | -16% | -36% | -40% | -32% | -36% | -5% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: INCY, PFE, LLY, ARVN, CRBU.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 1/30/2026 (YTD)
How Low Can It Go
| Event | PRLD | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -98.2% | -25.4% |
| % Gain to Breakeven | 5324.9% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -36.2% | -33.9% |
| % Gain to Breakeven | 56.8% | 51.3% |
| Time to Breakeven | 15 days | 148 days |
Compare to INCY, PFE, LLY, ARVN, CRBU
In The Past
Prelude Therapeutics's stock fell -98.2% during the 2022 Inflation Shock from a high on 2/10/2021. A -98.2% loss requires a 5324.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Prelude Therapeutics (PRLD)
AI Analysis | Feedback
- Prelude Therapeutics is like a startup version of a pharmaceutical giant such as Merck or Eli Lilly, but entirely focused on discovering and developing new cancer drugs that are still in clinical trials.
- Think of PRLD as a specialized biotech 'discovery lab' aiming to develop the next breakthrough cancer treatment, similar to how an early Regeneron or Gilead Sciences started before they had blockbuster drugs.
- PRLD is a high-risk, high-reward medical startup focused solely on finding experimental cancer cures, hoping one day to have a successful drug portfolio like Amgen or Genentech.
AI Analysis | Feedback
- PRT2527: A cyclin-dependent kinase 9 (CDK9) inhibitor currently in Phase 1 clinical trials for various hematologic and solid tumors.
- PRT1419: A myeloid cell leukemia 1 (MCL1) inhibitor currently in Phase 1 clinical trials for various hematologic and solid tumors.
- PRT3645: A cyclin-dependent kinase 4/6 (CDK4/6) inhibitor currently in preclinical development for solid tumors.
AI Analysis | Feedback
Prelude Therapeutics (PRLD) is a clinical-stage precision oncology company focused on the discovery and development of novel small molecule therapies for cancer. As a company in the research and development phase, Prelude Therapeutics does not currently have any approved products for commercial sale.
Therefore, Prelude Therapeutics does not have "major customers" in the traditional sense, whether they be other companies or individuals purchasing their products. Their operations are centered on advancing their drug candidates through preclinical and clinical trials, rather than selling products to end-users or distributors.
AI Analysis | Feedback
nullAI Analysis | Feedback
```htmlKris Vaddi, Ph.D. Chief Executive Officer
Dr. Vaddi founded Prelude Therapeutics in 2016 and has served as its Chief Executive Officer and a member of the Board of Directors since then. Prior to founding Prelude, he served as the Chief Executive Officer of Orsenix, LLC, a clinical-stage biotechnology company, from 2014 to 2016. Orsenix later sold its clinical candidate to Syros Pharmaceuticals. He was also a Founding Scientist and Executive Director at Incyte Corporation, where he initiated and led JAK research programs that resulted in the discovery, development, and approval of Jakafi® (ruxolitinib) and Olumiant® (baricitinib). Prelude Therapeutics was largely financed by private equity firms like Baker Bros and OrbiMed in its early stages.
Bryant D. Lim Chief Legal Officer, Corporate Secretary & Chief Financial Officer
Mr. Lim joined Prelude Therapeutics in 2023 as Chief Legal Officer and Corporate Secretary and was appointed Chief Financial Officer in February 2025, after serving as interim CFO since April 2024. He brings over 20 years of experience in pharma and biotech. Before joining Prelude, Mr. Lim was Chief Business Officer and General Counsel at Aceragen, Inc. (previously Idera Pharmaceuticals). He also served as Vice President of Legal and Global Chief Compliance Officer at Incyte Corporation. Earlier in his career, he was an associate general counsel at ViroPharma Incorporated, which was acquired by Shire Pharmaceuticals.
Peggy Scherle, Ph.D. Chief Scientific Officer
Dr. Scherle has served as Chief Scientific Officer at Prelude Therapeutics since 2018. Before joining Prelude, she held several roles at Incyte Corporation, most recently as Group Vice President, Discovery Biology and Preclinical Pharmacology, where she oversaw target validation and preclinical drug discovery efforts. Dr. Scherle was one of the original scientists at Incyte in 2002 and contributed to the discovery and development of JAK inhibitors like Jakafi® and Olumiant®. Her earlier experience includes scientific research positions with DuPont Pharmaceuticals Company and Bristol-Myers Squibb.
Andrew Combs, Ph.D. Chief Chemistry Officer
Dr. Combs is the Chief Chemistry Officer at Prelude Therapeutics, joining in 2019. He has over 27 years of experience as a medicinal chemist. Prior to Prelude, Dr. Combs held various roles at Incyte Corporation from 2003 until 2019, including Vice President of Discovery Chemistry. He previously worked at DuPont-Merck, DuPont Pharmaceuticals, and Bristol-Myers Squibb. Dr. Combs has co-invented more than 10 clinical candidates, including epacadostat and parsaclisib, which advanced to late-stage clinical trials in oncology.
Aimee Crombie, Ph.D. Senior Vice President & Head of Strategic Planning & Operations
Dr. Crombie is the Senior Vice President and Head of Strategic Planning & Operations at Prelude Therapeutics. Prior to joining Prelude, she was Vice President of Research at Trevena, Inc., where she managed drug discovery activities from target identification to drug candidate selection. She played a role in the discovery of several small molecules, including oliceridine, TRV734, and TRV250. Dr. Crombie also previously worked as a scientist at Pfizer and Wyeth.
AI Analysis | Feedback
The key risks to Prelude Therapeutics' (PRLD) business are primarily centered around its financial stability, the inherent uncertainties of clinical drug development, and intense competition within the oncology sector.
- Financial Instability and Funding Challenges: Prelude Therapeutics operates as a pre-revenue company with significant research and development expenses, leading to a rapid depletion of its cash reserves. The company's future hinges on its ability to secure additional funding, which could result in shareholder dilution. An analysis of the company's financial health, including a low Piotroski F-Score and an Altman Z-Score of -9.42, indicates a precarious financial position and a high risk of bankruptcy.
- Clinical Development and Regulatory Approval Risks: The unpredictability inherent in drug development poses substantial risks to Prelude Therapeutics. This includes the potential for unfavorable clinical trial results, delays in advancing drug candidates through various phases, and the challenges associated with obtaining regulatory approvals. For instance, the company's decision in November 2025 to pause the clinical development of its SMARCA2 degrader program (PRT3789) and strategically shift focus to other candidates like JAK2 and KAT6A programs, demonstrates the unpredictable nature and high costs involved in drug development.
- Intense Competition: Prelude Therapeutics operates in a highly competitive oncology market. The company faces significant challenges from other pharmaceutical firms, including those developing therapies targeting similar biological pathways, such as Pfizer, which is advancing a molecule into Phase 3 for breast cancer. To effectively compete, Prelude Therapeutics must demonstrate differentiated efficacy or safety profiles for its drug candidates.
AI Analysis | Feedback
The advanced clinical development and positive early data of competitor PRMT5 inhibitors, notably MRTX1719 (from Bristol Myers Squibb, acquired via Mirati Therapeutics), pose a significant emerging threat to Prelude Therapeutics' earlier-stage PRMT5 inhibitor program, PRT3789. MRTX1719 is in Phase 1/2 trials and has reported promising efficacy and safety data, particularly in MTAP-deleted cancers. In contrast, Prelude's PRT3789 is currently in IND-enabling studies. The potential for MRTX1719 to establish itself as a leading or standard-of-care therapy in PRMT5 inhibition before PRT3789 reaches advanced clinical stages could severely limit the market opportunity, commercial viability, and differentiation potential for Prelude's candidate.
AI Analysis | Feedback
Prelude Therapeutics' addressable market for its main products and services is as follows:
- For their first-in-class SMARCA2 degrader (PRT3789), Prelude Therapeutics believes there is a potential to benefit up to 70,000 US/EU cancer patients with the SMARCA4 mutation.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Prelude Therapeutics (PRLD) over the next 2-3 years:- Milestone and Royalty Payments from Strategic Partnerships: Prelude Therapeutics is expected to generate future revenue through milestone achievements and potential royalties from its existing and future strategic collaborations. An example includes the exclusive option agreement with Incyte for the JAK2V617F mutant selective inhibitor program, which includes an upfront payment and potential downstream milestones and royalties if Incyte exercises its option and advances the program globally. Additionally, the multi-year, multi-program partnership with AbCellera to develop first-in-class precision antibody drug conjugates (ADCs) could also yield milestone payments as these programs progress through discovery and development.
- New Collaboration and Licensing Agreements for Clinical Pipeline Candidates: The continued advancement of Prelude's lead clinical candidates, such as its oral SMARCA2 degrader (PRT7732), intravenous SMARCA2 degrader (PRT3789), and KAT6A degraders, could attract new pharmaceutical partners. Positive clinical data from these programs could lead to new collaboration and licensing agreements, typically involving significant upfront payments and future development and commercialization milestones, thereby driving revenue growth.
- Expansion and Deepening of Existing Collaborations: The success of Prelude’s ongoing strategic collaborations could lead to expanded agreements and additional financial contributions. For instance, the clinical trial collaboration with Merck to evaluate PRT3789 in combination with KEYTRUDA in SMARCA4-mutated cancers could potentially lead to broadened development plans or further financial arrangements if the Phase 2 study yields positive results. Similarly, the multi-program nature of the AbCellera partnership indicates potential for expansion into additional programs or indications, contributing to future revenue.
AI Analysis | Feedback
Share Issuance
- In January 2021, Prelude Therapeutics completed an upsized public offering, generating approximately $172.5 million in gross proceeds from the issuance of 2,875,000 shares of common stock at $60.00 per share.
- In December 2023, the company announced a private placement expected to yield approximately $25 million in gross proceeds through the sale of pre-funded warrants for 7,936,759 shares, with proceeds allocated to advance its SMARCA2 portfolio, working capital, and general corporate purposes.
- On November 3, 2025, Prelude Therapeutics announced a private placement of 6,250,000 non-voting shares at $4.00 per share to Incyte Corporation, raising $25 million to support ongoing research programs.
Inbound Investments
- In August 2020, Prelude Therapeutics closed a $50 million Series C financing round from existing institutional investors, including OrbiMed Advisors LLC, and a new investor, Fidelity Management & Research Company LLC, to support the growth and advancement of its pipeline.
- On November 4, 2025, Prelude Therapeutics announced an exclusive option agreement with Incyte Corporation, including $60 million in upfront capital ($35 million cash and a $25 million equity investment) for its JAK2V617F JH2 inhibitor program. The agreement also includes potential future clinical and regulatory milestones of up to $775 million and single-digit royalties.
Capital Expenditures
- Prelude Therapeutics reported capital expenditures of approximately -$183,000 over the last 12 months (ending approximately November 2025).
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Prelude Therapeutics Earnings Notes | 12/16/2025 | |
| Is Prelude Therapeutics Stock Built to Withstand a Pullback? | 10/17/2025 | |
| Day 5 of Gains Streak for Prelude Therapeutics Stock with 52% Return (vs. 18% YTD) [9/26/2025] | 09/27/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 19.91 |
| Mkt Cap | 10.3 |
| Rev LTM | 2,563 |
| Op Inc LTM | 577 |
| FCF LTM | -75 |
| FCF 3Y Avg | -114 |
| CFO LTM | 576 |
| CFO 3Y Avg | 279 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 27.5% |
| Rev Chg 3Y Avg | 23.4% |
| Rev Chg Q | 14.3% |
| QoQ Delta Rev Chg LTM | 3.4% |
| Op Mgn LTM | -4.1% |
| Op Mgn 3Y Avg | 13.8% |
| QoQ Delta Op Mgn LTM | 3.1% |
| CFO/Rev LTM | -42.2% |
| CFO/Rev 3Y Avg | 15.3% |
| FCF/Rev LTM | -52.8% |
| FCF/Rev 3Y Avg | 0.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 10.3 |
| P/S | 8.7 |
| P/EBIT | 5.7 |
| P/E | 7.2 |
| P/CFO | 5.2 |
| Total Yield | -2.0% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -12.0% |
| D/E | 0.1 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -2.7% |
| 3M Rtn | 13.7% |
| 6M Rtn | 34.5% |
| 12M Rtn | 17.9% |
| 3Y Rtn | -45.8% |
| 1M Excs Rtn | -2.0% |
| 3M Excs Rtn | 14.2% |
| 6M Excs Rtn | 27.7% |
| 12M Excs Rtn | 3.3% |
| 3Y Excs Rtn | -116.6% |
Price Behavior
| Market Price | $1.85 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 09/25/2020 | |
| Distance from 52W High | -53.5% | |
| 50 Days | 200 Days | |
| DMA Price | $2.01 | $1.32 |
| DMA Trend | up | up |
| Distance from DMA | -8.0% | 40.6% |
| 3M | 1YR | |
| Volatility | 179.2% | 196.3% |
| Downside Capture | 273.96 | 151.04 |
| Upside Capture | 342.83 | 182.30 |
| Correlation (SPY) | 7.7% | 14.5% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.31 | -1.30 | 2.40 | 2.34 | 1.47 | 1.68 |
| Up Beta | 9.40 | 6.97 | -7.25 | -1.61 | 0.85 | 1.66 |
| Down Beta | -3.58 | -0.15 | 4.70 | 5.48 | 1.88 | 1.54 |
| Up Capture | -434% | -202% | 424% | 380% | 289% | 197% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 8 | 20 | 32 | 67 | 127 | 344 |
| Down Capture | 479% | -656% | 242% | 82% | 129% | 112% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 12 | 20 | 28 | 56 | 119 | 386 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PRLD | |
|---|---|---|---|---|
| PRLD | 60.5% | 195.7% | 0.97 | - |
| Sector ETF (XLV) | 7.7% | 17.2% | 0.27 | 12.7% |
| Equity (SPY) | 16.1% | 19.2% | 0.65 | 14.6% |
| Gold (GLD) | 76.5% | 23.4% | 2.38 | -0.5% |
| Commodities (DBC) | 11.1% | 15.9% | 0.48 | 7.8% |
| Real Estate (VNQ) | 5.3% | 16.5% | 0.14 | 7.9% |
| Bitcoin (BTCUSD) | -18.9% | 39.9% | -0.43 | 4.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PRLD | |
|---|---|---|---|---|
| PRLD | -52.4% | 123.2% | -0.09 | - |
| Sector ETF (XLV) | 7.1% | 14.5% | 0.31 | 17.8% |
| Equity (SPY) | 14.0% | 17.1% | 0.65 | 20.9% |
| Gold (GLD) | 20.8% | 16.5% | 1.03 | 4.0% |
| Commodities (DBC) | 12.2% | 18.8% | 0.53 | 5.3% |
| Real Estate (VNQ) | 4.8% | 18.8% | 0.16 | 16.1% |
| Bitcoin (BTCUSD) | 21.1% | 57.5% | 0.56 | 10.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PRLD | |
|---|---|---|---|---|
| PRLD | -23.4% | 122.2% | 0.11 | - |
| Sector ETF (XLV) | 10.4% | 16.6% | 0.52 | 17.6% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 20.4% |
| Gold (GLD) | 15.6% | 15.3% | 0.85 | 4.0% |
| Commodities (DBC) | 8.5% | 17.6% | 0.40 | 5.0% |
| Real Estate (VNQ) | 5.9% | 20.8% | 0.25 | 15.3% |
| Bitcoin (BTCUSD) | 71.5% | 66.4% | 1.11 | 10.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/12/2025 | 8.9% | 24.4% | 26.7% |
| 8/14/2025 | 4.2% | 15.8% | 24.6% |
| 3/10/2025 | -9.0% | 1.2% | -11.9% |
| 11/6/2024 | -3.8% | -19.7% | -27.7% |
| 8/12/2024 | -6.9% | 2.2% | 5.5% |
| 5/7/2024 | -3.4% | -0.8% | -1.6% |
| 2/15/2024 | 33.0% | 13.8% | 33.6% |
| 11/1/2023 | 18.8% | 61.3% | 73.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 7 | 10 | 8 |
| # Negative | 10 | 7 | 9 |
| Median Positive | 8.5% | 14.5% | 25.6% |
| Median Negative | -3.8% | -10.9% | -12.3% |
| Max Positive | 33.0% | 61.3% | 73.4% |
| Max Negative | -9.0% | -19.7% | -41.4% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 03/10/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/12/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/15/2024 | 10-K |
| 09/30/2023 | 11/01/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/08/2023 | 10-Q |
| 12/31/2022 | 03/15/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
| 12/31/2021 | 03/17/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Combs, Andrew | Chief Chemistry Officer | Direct | Buy | 3272025 | 0.69 | 100,000 | 69,250 | 332,485 | Form |
| 2 | Vaddi, Krishna | CEO | Direct | Buy | 3272025 | 0.69 | 675,000 | 467,438 | 1,384,512 | Form |
| 3 | Vaddi, Krishna | CEO | Direct | Buy | 3242025 | 0.73 | 5,416 | 3,950 | 955,001 | Form |
| 4 | Vaddi, Krishna | CEO | Direct | Buy | 3242025 | 0.73 | 15,000 | 10,959 | 967,531 | Form |
| 5 | Vaddi, Krishna | CEO | Direct | Buy | 3182025 | 0.75 | 29,999 | 22,631 | 976,778 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.